Novo Nordisk responds to the restricted sales of "weight loss miracle drug" Wegovy in China: Global supply shortage, orderly supply launch in the Chinese market
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk responds to the limited sale of "weight loss miracle drug" Wegovy in China, stating that they will soon introduce the product to the Chinese market to meet the needs of a large number of obese patients. This drug is based on a GLP-1 receptor agonist and has been launched in over 10 countries worldwide, attracting widespread attention. Currently, Novo Nordisk has chosen to sell in limited quantities to address the high demand for this innovative drug in the market. Novo Nordisk China is working hard to increase the supply of GLP-1 class drugs
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: China Finance Online The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments